What's a Good P/E for Healthcare Stocks? (2026)

Every sector carries its own structural P/E range. Healthcare companies currently trade at a sector median of 25.5×, reflecting the combination of growth expectations, capital intensity, and margin profiles that define this corner of the market. Applying a blanket market-wide cutoff — “only buy stocks under 20×” — gives a distorted picture: a stock that looks expensive relative to the S&P 500 average may be trading at a genuine discount to its direct sector peers, while a stock that appears cheap on an absolute basis might be overpriced within its own competitive cohort.

The right framework is sector-relative P/E. By anchoring each stock's multiple to the median P/E of its own sector rather than the whole market, you strip out the structural premium (or discount) that the sector commands and focus on individual valuation signal. Of the 221 Healthcare stocks in the Tessera Alpha factor panel right now, 110 carry a positive trailing P/E that sits below the sector median. A selection of the largest such names, ordered by how far they trade below the median, appears in the table below.

Tessera Alpha rescans the full panel weekly, computing median P/E from trailing twelve-month earnings. Negative-earnings companies are excluded from the median to avoid skew. The quality score column maps each company's composite factor score — covering profitability, balance-sheet strength, and capital efficiency — to a 0–100 scale, so you can quickly distinguish a temporarily cheap stock from one that is cheap for a reason. The sector median shown here is updated on every weekly rescan; the trend chart below traces how that median has moved over roughly the past year.